Status:
COMPLETED
Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?
Lead Sponsor:
Karolinska University Hospital
Collaborating Sponsors:
Karolinska Institutet
Conditions:
Primary Hyperparathyroidism
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
Patients with primary hyperparathyroidism (pHPT) often present with fatigue, psychological and cognitive symptoms. Improvement in these symptoms after parathyroid adenomectomy (PTX) has been reported....
Detailed Description
The study evaluates if short-term treatment with calcimimetics may be used for patients with PHPT as a relevant guide in the decision of when to choose parathyroid surgery, by predicting the outcome o...
Eligibility Criteria
Inclusion
- Primary hyperparathyroidism
- Scheduled for parathyroid surgery
- Age \>40
- Ability to participate in all tests included in the study model
- Signed consent
Exclusion
- Pregnancy
- Breast feeding
- Fertile woman not using contraceptives (IUD or pills)
- Impaired kidney function, GFR \< 40 ml/min
- Intolerance to Mimpara®
- Previously treated with Mimpara®
- Participating in other ongoing clinical study
- Epilepsy
- Severe hepatic impairment
- Hypotension
- Heart failure (NYHA class 3-4, symptoms with minimal exertion)
- Medication with ketoconazole (oral) or tricyclic antidepressants
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT02227264
Start Date
June 1 2014
End Date
December 31 2021
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska University Hospital
Stockholm, Sweden, 171 76